| 0.924 0.078 (9.17%) | 09-16 16:00 | |||||||||||||
|
|
| Short term |   |
|||
| Mid term |  |
|||
| Targets | 6-month : | 1.28 | 1-year : | 1.47 |
| Resists | First : | 1.1 | Second : | 1.25 |
| Pivot price | 0.96  |
|||
| Supports | First : | 0.84 | Second : | 0.7 |
| MAs | MA(5) : | 0.89 |
MA(20) : | 1 |
| MA(100) : | 1.37 |
MA(250) : | 2.75 |
|
| MACD | MACD : | -0.1 |
Signal : | -0.1 |
| %K %D | K(14,3) : | 10 |
D(3) : | 6.1 |
| RSI | RSI(14): 38.2 |
|||
| 52-week | High : | 8.61 | Low : | 0.84 |
Price has closed above its short-term moving average. Short-term moving average is currently below mid-term; and below long-term moving average. From the relationship between price and moving averages: This stock is NEUTRAL in short-term; and BEARISH in mid-long term.[ SXTP ] has closed above bottom band by 35.0%. Bollinger Bands are 21.2% narrower than normal. The current width of the bands does not suggest anything about the future direction or movement of prices.
| If tomorrow: | Open lower | Open higher |
| High: | 0.96 - 0.97 | 0.97 - 0.98 |
| Low: | 0.85 - 0.85 | 0.85 - 0.86 |
| Close: | 0.91 - 0.92 | 0.92 - 0.94 |
60 Degrees Pharmaceuticals, Inc. is a specialty pharmaceutical firm dedicated to developing and bringing to market therapies aimed at preventing and treating infectious diseases within the United States. The company currently offers Arakoda, an approved medication for malaria prophylaxis. Its pipeline includes several investigational drugs: Tafenoquine, in its 'Arakoda regimen' formulation, is undergoing Phase IIb clinical trials for potential use against COVID-19. Additionally, Tafenoquine is the subject of Phase IIA clinical studies for conditions such as babesiosis, fungal pneumonias, and candidiasis. Another candidate, Celgosivir, is being developed to address Zika, various respiratory viruses, and dengue fever. Further strengthening its development efforts, 60 Degrees Pharmaceuticals holds a patent license agreement with Tufts Medical Center, collaborating to advance Tafenoquine specifically for the treatment and prevention of babesiosis. The company was established in 2010 and maintains its corporate headquarters in Washington, D.C.
Fri, 11 Sep 2026
SXTP: Label expansion for ARAKODA into babesiosis aims for regulatory milestones and launch by 2028 - TradingView
Tue, 08 Sep 2026
60 Degrees Pharma flags going-concern risk - Stock Titan
Thu, 03 Sep 2026
60 Degrees Pharmaceuticals to Present at H.C. Wainwright 28th Annual Global Investment Conference - Quiver Quantitative
Thu, 03 Sep 2026
A pharmaceutical company will post a public presentation Sept. 11. Its management will meet investors in New York. - Stock Titan
Thu, 03 Sep 2026
60 Degrees Pharmaceuticals Announces Participation in H.C. Wainwright 28th Annual Global Investment Conference - Yahoo Finance
Wed, 26 Aug 2026
60 DEGREES PHARMACEUTICALS, INC. SEC Filing (Aug 26, 2026) - Stock Titan
| Price to Book Value: P/BV, a ratio used to compare book value to its current market price, to gauge whether a stock is valued properly. |
Neutral |
| Price to Earnings: PE, the ratio for valuing a company that measures its current share price relative to its earnings per share (EPS). |
Underperform |
| Discounted cash flow: DCF, a valuation method used to estimate the value of an investment based on its expected future cash flows. |
Underperform |
| Return on Assets: ROA, indicates how profitable a company is in relation to its total assets, how efficiently uses assets to generate a profit. |
Underperform |
| Return on Equity: ROE, a measure of financial performance calculated by dividing net income by equity. a gauge of profitability and efficiency. |
Underperform |
| Debt to Equity: evaluate financial leverage, reflects the ability of equity to cover outstanding debts in the event of a business downturn. |
Neutral |
|
Exchange:
NASDAQ
|
|
|
Sector:
Healthcare
|
|
|
Industry:
Biotechnology
|
|
| Shares Out | 0 (M) |
| Shares Float | 4 (M) |
| Held by Insiders | 2.44e+006 (%) |
| Held by Institutions | 19.3 (%) |
| Shares Short | 146 (K) |
| Shares Short P.Month | 0 (K) |
| EPS | -8.5e+006 |
| EPS Est Next Qtrly | 0 |
| EPS Est This Year | 0 |
| EPS Est Next Year | 0 |
| Book Value (p.s.) | 0 |
| Profit Margin | 0 % |
| Operating Margin | -1 % |
| Return on Assets (ttm) | 92.4 % |
| Return on Equity (ttm) | -127.2 % |
| Qtrly Rev. Growth | 1.21e+006 % |
| Gross Profit (p.s.) | -12.8 |
| Sales Per Share | -131.05 |
| EBITDA (p.s.) | -811024 |
| Qtrly Earnings Growth | -2.7 % |
| Operating Cash Flow | 0 (M) |
| Levered Free Cash Flow | -9 (M) |
| PE Ratio | -0.01 |
| PEG Ratio | 0 |
| Price to Book value | 0 |
| Price to Sales | -0.01 |
| Price to Cash Flow | -0.9 |
| Dividend | 0 |
| Forward Dividend | 277180 |
| Dividend Yield | 0% |
| Dividend Pay Date | Invalid DateTime. |
| Ex-Dividend Date | Invalid DateTime. |
|
|
|
|
|
|
|
|
|